VENTAS REIT INC (VTR)
Sector: Real Estate
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Real Estate
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for VTR
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| VTR | Independent Director | 58 | ["35 years of experience in the life sciences industry", "Public company executive", "Operator and serial entrepreneur", "Expertise in commercial operations, global marketing, and corporate and business development", "Former CEO of AveXis, growing it from four employees to a fully integrated global public company"] | ["Compensation", "Nominating", "Governance and Corporate Responsibility", "Nominating, Governance and Corporate Responsibility Committee"] | 2026 |
Biography sourced from the proxy statement filing.
Mr. Nolan brings to our Board 35 years of experience in the life sciences industry as a public company executive, operator and serial entrepreneur. His diverse functional expertise includes commercial operations, global marketing, and corporate and business development. Mr. Nolan previously served as CEO of AveXis (NYSE: AVXS), which he grew from four employees to a fully integrated global public company with research, clinical, regulatory, manufacturing and commercial operations that was ultimately sold to Novartis for $8.7 billion. Professional Experience: Taysha Gene Therapies, Inc. (NASDAQ: TSHA) Chief Executive Officer (since 2022), Chairman of the Board (since 2020); President, Nolan Capital, LLC, an investment fund (since 2019); President and Chief Executive Officer, AveXis, Inc. (formerly NASDAQ: AVXS), a gene therapy company (2015-2018); Chief Business Officer, InterMune, Inc. (formerly NASDAQ: ITMN), a biopharmaceutical company (2013-2015); Chief Commercial Officer, Reata Pharmaceuticals, Inc. (NASDAQ: RETA), a pharmaceuticals company (2011-2012); Chief Commercial Officer and President, Lundbeck, Inc., a U.S. affiliate of H. Lundbeck A/S, a Danish pharmaceuticals company (2009-2010). Private Boards and Community Service: Chairman of the Board, Jaguar Gene Therapy, LLC; Chairman of the Board, Affinia Therapeutics Inc.; Chairman of the Board, Encoded Therapeutics, Inc.; Advisory Board Member, Goldman Sachs Life Sciences Fund.